Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22252589 | 1.00 | IRAK4 (0.38) | IRAK4HTR4TLR7CYP11B2KCNH2 | |
| SCHEMBL22252587 | 1.00 | IRAK4 (0.38) | IRAK4HTR4TLR7CYP11B2KCNH2 | |
| SCHEMBL22252588 | 0.91 | HTR4 (0.40) | HTR4KCNH2CNR2 | |
| SCHEMBL23194296 | 0.83 | MAPT (0.38) | HTR4TLR7KCNH2TLR8TLR9 | |
| SCHEMBL11914063 | 0.79 | CHRM2 (0.34) | — | |
| SCHEMBL25617367 | 0.74 | KDM4E (0.40) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25859573 | 0.74 | KDM4E (0.40) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17239438 | 0.73 | NPC1 (0.44) | TLR7TLR8NAMPTCNR1CNR2 | |
| SCHEMBL20696927 | 0.72 | SCD (0.42) | IRAK4HTR4TLR7CYP11B2KCNH2 | |
| SCHEMBL20696929 | 0.72 | SCD (0.42) | IRAK4HTR4TLR7CYP11B2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174264-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | IRAK4 30/4885HTR4 3724/4885TLR7 1174/4885 |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | IRAK4 30/4885HTR4 3724/4885TLR7 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.